Multitypic Recombinant Adenovirus Vaccines Against HPV

This invention is a vaccine against human papillomavirus infection consisting of recombinant adenoviruses that are engineered to include peptides of the human papillomavirus 16 minor capsid protein (L2). The L2 sequences are displayed on the outside of the adenovirus particles, where they induce immunity directed against HPV16 and, since HPVL2 induces multitypic antibody, against other HPV types as well. The preferred vaccines will be viable and will induce immunity as they replicate in vaccinated individuals, although non-replicating vaccines that employ the capsid-display strategy also can be produced. Description (Set) Proposed Use (Set) Cervical cancer is caused by the HPV infection and kills about 200,000 women annually. The currently licensed HPV vaccine, though effective, protects against only a subset of the multiple HPV types that induce disease. In contrast, live vaccines will confer multitypic immunity, protecting against most or all HPV types. In addition, live vaccines using this design are anticipated to have the advantages of low cost of production and administration, and protection by a single oral dose. This also contrasts with existing papillomavirus vaccines, which are relatively expensive to produce and administer and require repeated injections. Thus, the vaccines described here have the distinct advantages of broad protection and relative economy.

Inventor(s): Ketner, Gary W.

Type of Offer: Licensing



« More Medical Patents

---